CN110856695A - Application of hot spring water in cosmetics - Google Patents
Application of hot spring water in cosmetics Download PDFInfo
- Publication number
- CN110856695A CN110856695A CN201810971992.0A CN201810971992A CN110856695A CN 110856695 A CN110856695 A CN 110856695A CN 201810971992 A CN201810971992 A CN 201810971992A CN 110856695 A CN110856695 A CN 110856695A
- Authority
- CN
- China
- Prior art keywords
- spring water
- hot spring
- water
- substance
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 123
- 239000002537 cosmetic Substances 0.000 title claims abstract description 25
- 210000003630 histaminocyte Anatomy 0.000 claims abstract description 45
- 230000024883 vasodilation Effects 0.000 claims abstract description 11
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 10
- 229910001425 magnesium ion Inorganic materials 0.000 claims abstract description 10
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 210000003491 skin Anatomy 0.000 claims description 62
- 239000012528 membrane Substances 0.000 claims description 9
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims description 7
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 229910003641 H2SiO3 Inorganic materials 0.000 claims description 4
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 4
- 239000012498 ultrapure water Substances 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 23
- 229910001415 sodium ion Inorganic materials 0.000 abstract description 7
- 229910001427 strontium ion Inorganic materials 0.000 abstract description 7
- 239000011734 sodium Substances 0.000 abstract description 6
- 239000011575 calcium Substances 0.000 abstract description 4
- 239000011777 magnesium Substances 0.000 abstract description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 37
- 102100024304 Protachykinin-1 Human genes 0.000 description 37
- 101800003906 Substance P Proteins 0.000 description 37
- 210000004204 blood vessel Anatomy 0.000 description 23
- 230000037307 sensitive skin Effects 0.000 description 20
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 18
- 230000037311 normal skin Effects 0.000 description 16
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 12
- 229960003957 dexamethasone Drugs 0.000 description 12
- 230000002792 vascular Effects 0.000 description 10
- -1 Iron ion Chemical class 0.000 description 9
- 229960002504 capsaicin Drugs 0.000 description 9
- 235000017663 capsaicin Nutrition 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 7
- 238000010186 staining Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229910001416 lithium ion Inorganic materials 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 229950003937 tolonium Drugs 0.000 description 5
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
- 206010047141 Vasodilatation Diseases 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- 229910001431 copper ion Inorganic materials 0.000 description 3
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 229910001437 manganese ion Inorganic materials 0.000 description 3
- 229910001414 potassium ion Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101710204736 Platelet endothelial cell adhesion molecule Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012764 semi-quantitative analysis Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000736131 Sphingomonas Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000020682 bottled natural mineral water Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of hot spring water in cosmetics. Hot spring water is used as anti-allergic active ingredient in cosmetics; the hot spring water per liter contains the following components: na (Na)+75‑114mg、Ca2+16‑24mg、Mg2+0.33-0.5mg and Sr+0.36-0.55 mg. Sodium, calcium, magnesium and strontium ions in the hot spring water can synergistically inhibit vasodilation or reduce the degranulation rate of mast cells, so that the anti-sensitivity effect is achieved.
Description
Technical Field
The invention relates to the field of cosmetics, in particular to application of hot spring water in cosmetics.
Background
In recent years, sensitive skin tends to increase with changes in the surrounding environment. Such as long-term exposure to dust, powder, metal contaminants, etc., can sensitize the skin of a person; improper living habits of people can also damage the skin, and for example, the skin can become sensitive and fragile due to insufficient long-term sleep, excessive pressure, frequent eating of spicy and irritating foods, improper maintenance and the like, so that the resistance of the skin is weakened. Sensitive skin is highly intolerant, and the skin in a sensitive state is intolerant to slight external stimulation, so that various symptoms such as pruritus, stabbing pain, burning, tightness and the like are easily caused. Sensitive skin is characterized by itching, stinging and flushing and fever in the sense of the skin, and is physiologically characterized by increased degranulation rate of dermal mast cells and enlarged blood vessel area, respectively.
Mast cells (mast cells) are widely distributed in the dermis, and the cytoplasm of the mast cells contains chromophilous coarse particles, so that when external stimulation is applied, medium substances (histamine, heparin, tryptase and the like) stored in the cells are released, and skin itching and stinging are caused. Therefore, sensitive skin is usually accompanied with degranulation of dermal mast cells, and the sensitivity of the skin is increased along with the increase of degranulation of the mast cells. Therefore, the influence of the active substance on the degranulation rate of the mast cells can be studied, and whether the active substance has the anti-allergic effect or not can be presumed.
The blood vessels are widely distributed in human skin (except epidermis), sensitive skin is usually accompanied with blood vessel expansion, so that the permeability of the blood vessels is increased, the skin is red and swollen, and the skin is heated, and the sensitivity of the skin is deepened along with the deepening of the expansion degree of the blood vessels. The Platelet-endothelial cell adhesion molecule (PECAM-1), also known as CD31, has a molecular weight of 130kDa and is normally localized in vascular endothelial cells. By immunohistochemical detection of CD31, the area of the blood vessels can be determined, thereby inferring whether the active has anti-sensitivity efficacy.
The Shangdaus-Ningqing Tanggula mountain area located in the Maolayas geotropics of the Ministry of Moghas, Tibet, Lasa, is provided with a hot spring area at an altitude of 4260-4360 m, the hot spring area is warm and humid in climate, and the area is a solar hot spring area.
The Japanese hot spring water is hot spring water, the surface water temperature can reach 81 ℃, the Japanese hot spring water is rich in 7 trace elements, meets the water quality standard of the national physical (medical) treatment hot spring water, is rich in 21 mineral elements, has a pH value of 6.5-8.5, is moderately alkalescent, is greatly beneficial to a human body, and has the health-care effects of promoting blood circulation to remove blood stasis, regulating blood pressure and the like. Furthermore, the hot spring water contains a large amount of natural probiotics. The probiotic bacteria mainly belong to sphingomonas of sphingolipid monadaceae, can produce extracellular polysaccharide high polymer, and have biological function. In addition, the hot spring also contains a large amount of sulfur element, which inhibits the growth of some bacteria.
However, there is a recent literature reporting that Japanese hot spring water is used in cosmetics having anti-allergy effects.
Disclosure of Invention
The invention aims to provide the anti-sensitivity application of hot spring water in cosmetics and the cosmetics containing the same. The dermal mast cell degranulation rate and the blood vessel area of the skin are related to the skin sensitivity state, the larger the area of the blood vessel expansion is, the higher the dermal mast cell degranulation rate is, and the deeper the skin sensitivity is, and the cosmetic containing the hot spring water can remarkably relieve the sensitivity by inhibiting the vasodilatation or reducing the degranulation rate of the mast cell, so that the anti-sensitivity effect is achieved.
The inventor researches and discovers that: the spring water with multiple temperature in the county of Mozhuchai county of Lassa in Tibet can inhibit vasodilation or reduce the degranulation rate of mast cells, so as to achieve the anti-sensitivity effect. Therefore, the inventor performs characterization analysis on the components of Japanese hot spring water, and finds that sodium ions, calcium ions, magnesium ions and strontium ions in the hot spring water can synergistically inhibit vasodilation or reduce the degranulation rate of mast cells through a large amount of researches, so that the anti-sensitivity effect is achieved.
Finally, the present invention solves the above technical problems by the following technical solutions.
The invention provides anti-allergic effect of hot spring water in cosmetics, wherein the hot spring water is used as an anti-allergic active ingredient in the cosmetics; the hot spring water contains the following components per liter: na (Na)+75-114mg、Ca2+16-24mg、Mg2+0.33-0.5mg and Sr+0.36-0.55mg。
In the present invention, the pH of the thermal spring water is generally 6.8 to 7.5, preferably 6.95 to 7.02.
In the invention, Na is added into each liter of hot spring water+The content of (B) is preferably 94.4 mg.
In the invention, the Ca is added in each liter of the hot spring water2+The content of (B) is preferably 19.9 mg.
In the invention, the Mg is added in each liter of the hot spring water2+The content of (B) is preferably 0.42 mg.
In the invention, the Sr is added into each liter of the hot spring water+The content of (B) is preferably 0.46 mg.
In the present invention, each liter of the thermal spring water preferably further contains the following components: k+5.9-8.9mg、Li+0.4-0.63mg、Mn2+0.0168-0.0252mg、F-1.2-1.8mg、SO4 2-30-46mg and H2SiO320-32 mg; more preferably K+7.4mg、Li+0.52mg、Mn2+0.021mg、F-1.5mg、SO4 2-37.9mg and H2SiO326.2mg。
In the present invention, the thermal spring water may further contain other trace elements or ions, such as Zn, Cu, Fe, Al, Cl and/or CO3 2-The term "very small amount" as used herein means that the content thereof cannot be detected by a conventional method.
In the present invention, the source of the thermal spring water is not particularly limited as long as the thermal spring water includes sodium, calcium, magnesium, and strontium ions within the above content range. Preferably, the water intake of the hot spring water is a multi-day hot spring which is located in the multi-day county of Moghai city, the altitude is 4000 meters, the surface temperature is generally between 65 and 83 ℃, and the pH value is between 6.8 and 7.5.
Wherein, the specific water intake time, water intake site, water intake depth and the like of the hot spring are different, the contents of the components in the hot spring are different, but as long as the required component content is within the range defined by the invention, the effect of inhibiting the vasodilatation of the skin or reducing the degranulation rate of mast cells can be realized, thereby achieving the anti-allergy effect.
In the invention, the hot spring water is preferably sterilized by filtration through a filter membrane, and the pore diameter of the filter membrane is preferably 0.22 μm.
In the present invention, the anti-sensitive active ingredient is an active ingredient that inhibits vasodilation of the skin or reduces the degranulation rate of mast cells.
In the present invention, the cosmetic is a term of art, and refers to chemical industrial products or fine chemical products, including skin care products and color cosmetics, which are applied to any part of the surface of the human body, such as skin, hair, nails, lips, and teeth, by painting, spraying, or the like, in order to clean, maintain, beautify, modify, and change the appearance of the body, or to correct the odor of the body and maintain a good state.
In the present invention, the kind of the cosmetic is not particularly limited, and may be a basic cosmetic, a face makeup cosmetic, a body makeup cosmetic, or the like. In the present invention, the formulation of the cosmetic is not particularly limited, and may be appropriately selected depending on the purpose.
In the invention, when the hot spring water is applied to cosmetics, the hot spring water is generally cooled from a higher temperature when the hot spring water is taken to a normal temperature for use, wherein the normal temperature is a technical term in the field and is generally 15-35 ℃.
In the invention, when the hot spring water is applied to cosmetics, the hot spring water is preferably diluted by water except the hot spring water, the concentration of the diluted hot spring water is preferably 0.1-5%, more preferably 0.5-1%, and the percentage is the percentage of the volume of the hot spring water to the total volume of the hot spring water and the water except the hot spring water; wherein the water other than the thermal spring water is of a type of water conventionally used in cosmetics, including deionized water, distilled water, ultrapure water or the like, preferably deionized water.
On the basis of the common knowledge in the field, the above preferred conditions can be combined randomly to obtain the preferred embodiments of the invention.
The reagents and starting materials used in the present invention are commercially available.
The positive progress effects of the invention are as follows:
the invention discovers for the first time that sodium, calcium, magnesium and strontium ions in hot spring water in more than one day in more than one county of Moghania conka county in Tibet can synergistically inhibit vasodilatation or reduce the degranulation rate of mast cells, thereby achieving the anti-sensitivity effect.
Drawings
Fig. 1 is a graph comparing the vascular area and degranulation rate of a sensitive skin model obtained by treating excised skin with 10 μ M P substance and 0.3 μ M capsaicin in effect examples 2-3, wherein a is a graph of the vascular area of a normal skin model, b is a graph of the vascular area of a sensitive skin model obtained after the substance P treatment, c is a graph of the vascular area of a sensitive skin model obtained after the capsaicin treatment, d is a graph of the mast cell degranulation rate of a normal skin model, e is a graph of the mast cell degranulation rate of a sensitive skin model obtained after the substance P treatment, and f is a graph of the mast cell degranulation rate of a sensitive skin model obtained after the capsaicin treatment.
FIG. 2 is a graph showing the comparison of the blood vessel area measured by immunohistochemistry in each group of example 2, wherein a is a blood vessel area of a normal skin model, b is a blood vessel area of a skin model treated with 10. mu.M of substance P, c is a blood vessel area of a skin model treated with 10. mu.M of substance P and hot spring water at a final concentration of 0.5%, and d is a blood vessel area of a skin model treated with 10. mu.M of substance P and 0.04. mu.g/mL of dexamethasone.
FIG. 3 is a semi-quantitative comparison of vascular area for each group, where "NT" is a normal skin model blank control group, "NT + P substance" is a 10 μ M substance P treated skin model, "0.5% Weak + substance P" is a 10 μ M substance P and final 0.5% thermal spring water co-treated skin model, "0.04 μ M substance + substance P" is a 10 μ M substance P and 0.04 μ g/mL dexamethasone co-treated skin model.
Fig. 4 is a graph comparing the mast cell degranulation rates obtained by toluidine blue staining of the groups in effect example 3, in which a is a graph of the mast cell degranulation rate of a normal skin model, b is a graph of the mast cell degranulation rate of a sensitive skin model obtained after treatment with substance P of 10 μ M, c is a graph of the mast cell degranulation rate of a skin model treated with substance P of 10 μ M and hot spring water of 0.5% final concentration, and d is a graph of the mast cell degranulation rate of a skin model treated with substance P of 10 μ M and dexamethasone of 0.04 μ g/mL.
FIG. 5 is a graph of immunofluorescence semi-quantitative analysis of mast cell degranulation for each group, wherein "NT" is a normal skin model blank control group, "NT + P substance" is a 10 μ M substance P treated skin model, "0.5% Wen + substance P" is a 10 μ M substance P and final 0.5% hot spring water co-treated skin model, "0.04 μ M substance + substance P" is 10 μ M substance P and 0.04 μ g/mL dexamethasone co-treated skin model.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.
In the following examples, the hot spring water is obtained from hot spring water in the county of Moghai city, Tibetan, over 4000 meters above sea level and at a surface temperature of 65-83 deg.C.
In the following examples, the content of the components in the hot spring water is detected by the method for detecting the natural mineral water for drinking according to the national standard GB/T8538-.
In the examples described below, other starting materials and reagents were used which were commercially available.
Examples 1 to 2
Preparation of hot spring active matter
The hot spring water is filtered and sterilized by a filter membrane, and the aperture of the filter membrane is 0.22 mu m.
The diurnal hot spring water used in examples 1-2 had a pH of 6.95-7.02 and the composition is shown in Table 1 below.
TABLE 1
| Composition (I) | Unit of | Measurement of content |
| Sodium ion | mg/L | 94.4 |
| Calcium ion | mg/L | 19.9 |
| Potassium ion | mg/L | 7.4 |
| Magnesium ion | mg/L | 0.42 |
| Zinc ion | mg/L | Not detected (<0.005) |
| Strontium ion | mg/L | 0.46 |
| Copper ion | mg/L | Not detected (<0.0001) |
| Lithium ion | mg/L | 0.52 |
| Manganese ion | mg/L | 0.021 |
| Iron ion | mg/L | Not detected (<0.005) |
| Meta-silicic acid | mg/L | 26.2 |
| Aluminum ion | mg/L | Not detected (<0.001) |
| Selenium ion | mg/L | Not detected (<0.001) |
| Carbonate radical | mg/L | Not detected (<0.5) |
| Chloride ion | mg/L | Not detected (<0.1) |
| Sulfate radical | mg/L | 37.9 |
| Fluoride ion | mg/L | 1.5 |
In examples 1-2, diurnal thermal spring water actives were formulated as follows in table 2.
TABLE 2
Note: the percentage is the percentage of the volume of the hot spring water to the total volume of the hot spring water and the deionized water.
Example 3
Preparation of hot spring active matter
The hot spring water is filtered and sterilized by a filter membrane, and the aperture of the filter membrane is 0.22 mu m.
The pH of the diurnal hot spring water used in this example was between 6.95 and 7.02, and the composition is shown in Table 3 below.
TABLE 3
| Composition (I) | Unit of | Measurement of content |
| Sodium ion | mg/L | 75.5 |
| Calcium ion | mg/L | 16.0 |
| Potassium ion | mg/L | 8.9 |
| Magnesium ion | mg/L | 0.5 |
| Zinc ion | mg/L | Not detected (<0.005) |
| Strontium ion | mg/L | 0.55 |
| Copper ion | mg/L | Not detected (<0.0001) |
| Lithium ion | mg/L | 0.46 |
| Manganese ion | mg/L | 0.0168 |
| Iron ion | mg/L | Not detected (<0.005) |
| Meta-silicic acid | mg/L | 32 |
| Aluminum ion | mg/L | Not detected (<0.001) |
| Selenium ion | mg/L | Not detected (<0.001) |
| Carbonate radical | mg/L | Not detected (<0.5) |
| Chloride ion | mg/L | Not detected (<0.1) |
| Sulfate radical | mg/L | 30 |
| Fluoride ion | mg/L | 1.8 |
And adding distilled water into 10mL of the hot spring water for dilution to obtain the active matter of the daily hot spring water with the final concentration of 0.5%, wherein the percentage is the percentage of the volume of the hot spring water in the total volume of the hot spring water and the deionized water. The results of the measurements of the area of the skin vessels and the degranulation rate of dermal mast cells carried out according to the methods of effect examples 1-3 show that the effect of hot spring water at this concentration is comparable to that of example 1, and that hot spring water at this concentration can significantly ease sensitivity by inhibiting vasodilation or reducing the degranulation rate of mast cells.
Example 4
Preparation of hot spring active matter
The hot spring water is filtered and sterilized by a filter membrane, and the aperture of the filter membrane is 0.22 mu m.
The pH of the diurnal hot spring water used in this example was between 7.0 and 7.1, and the composition is shown in Table 4 below.
TABLE 4
| Composition (I) | Unit of | Measurement of content |
| Sodium ion | mg/L | 114 |
| Calcium ion | mg/L | 24 |
| Potassium ion | mg/L | 5.9 |
| Magnesium ion | mg/L | 0.33 |
| Zinc ion | mg/L | Not detected (<0.005) |
| Strontium ion | mg/L | 0.36 |
| Copper ion | mg/L | Not detected (<0.0001) |
| Lithium ion | mg/L | 0.63 |
| Manganese ion | mg/L | 0.0252 |
| Iron ion | mg/L | Not detected (<0.005) |
| Meta-silicic acid | mg/L | 20 |
| Aluminum ion | mg/L | Not detected (<0.001) |
| Selenium ion | mg/L | Not detected (<0.001) |
| Carbonate radical | mg/L | Not detected (<0.5) |
| Chloride ion | mg/L | Not detected (<0.1) |
| Sulfate radical | mg/L | 46 |
| Fluoride ion | mg/L | 1.2 |
And (3) adding 10mL of the hot spring water into ultrapure water for dilution to obtain the daily multi-hot spring water active matter with the final concentration of 0.5%, wherein the percentage is the percentage of the volume of the hot spring water in the total volume of the hot spring water and the ultrapure water. The results of the measurements of the area of the skin vessels and the degranulation rate of dermal mast cells carried out according to the methods of effect examples 1-3 show that the effect of hot spring water at this concentration is comparable to that of example 1, and that hot spring water at this concentration can significantly ease sensitivity by inhibiting vasodilation or reducing the degranulation rate of mast cells.
Effect example 1
Determination of anti-allergic efficacy
The method comprises the following steps of obtaining skin tissues according to requirements of an ethical committee, removing redundant adipose tissues, subcutaneous tissues and more abrupt hairs, drilling biopsy tissues by using a puncher, placing a bracket in a flat dish before placing the tissues in the flat dish for culture, placing hexagonal filter paper, adding a culture medium DMEM (Gibco), finally placing a tissue block, placing the skin in a sample receiving small box after 24 hours, enabling the liquid level of the culture medium to just contact with the skin and not to exceed the epidermis, simultaneously adding a certain amount of P substance/capsaicin and warm spring water or dexamethasone with different concentrations into the culture medium for culture for 24 hours, fixing the skin in vitro in 10% formalin, dehydrating, embedding by using paraffin, and slicing to obtain a paraffin section with the thickness of 5 mu m.
Effect example 2
Blood vessel area size determination (CD31 immunohistochemistry)
Effect 5 μm thick paraffin sections (each derived from an in vitro skin model cultured in different media) prepared in example 1 were used to determine the expression level of CD31 in the skin model by immunohistochemical examination. The paraffin sections were immersed in 0.01M sodium citrate buffer (pH 6.0), immersed at 100 ℃ for 30 minutes, and then cooled to room temperature within 30 minutes. CD31 primary antibody (M0823, Dako) incubation was performed at room temperature for 1 hour, followed by staining with the Dako strept ABC complex/HRP kit according to the manufacturer's instructions. Cell nuclei were stained with hematoxylin incubation for 5 minutes at room temperature, and then photographed under a light microscope (Zeiss AX10) at 25 × magnification to obtain fig. 1a, 1b, 1c and 2.
Effect example 3
Mast cell degranulation assay (toluidine blue staining)
Effect using paraffin sections of 5 μm thickness prepared in example 1 (each derived from an in vitro skin model cultured in different media), after deparaffinization and rehydration, toluidine blue staining was performed for 30min, and the sections were dehydrated directly and observed by photographing under an optical microscope (Zeiss Axio Scope a1) at 25 × magnification to obtain fig. 1d, fig. 1e, fig. 1f and fig. 4.
The experimental results were analyzed using Microsoft Excel statistical software. Pairwise comparisons were performed using a t-test, with P <0.05 indicating statistical differences, marked with an "+". Image analysis Image-Pro plus7.0 was used for processing analysis.
Fig. 1 is a graph comparing the vascular area and mast cell degranulation of a sensitive skin model and a normal skin model obtained by treating excised skin with 10 μ M P substance and 0.3 μ M capsaicin (concentration refers to the final concentration of substance P or capsaicin in the total culture medium) in effect examples 2-3, in which a is a graph of the vascular area of the normal skin model, b is a graph of the vascular area of the sensitive skin model obtained after the substance P treatment, c is a graph of the vascular area of the sensitive skin model obtained after the capsaicin treatment, d is a graph of the mast cell degranulation of the normal skin model, e is a graph of the mast cell degranulation of the sensitive skin model obtained after the substance P treatment, and f is a graph of the mast cell degranulation of the sensitive skin model obtained after the capsaicin treatment. As shown in fig. 1, substance P and capsaicin stimulated the in vitro skin model to obtain a sensitive skin model with enlarged blood vessel area and increased dermal mast cell degranulation rate relative to the normal skin model.
FIG. 2 is a graph showing the comparison of the blood vessel area measured by immunohistochemistry in each group of example 2, wherein a is a blood vessel area of a normal skin model, b is a blood vessel area of a skin model treated with 10. mu.M of substance P, c is a blood vessel area of a skin model treated with 10. mu.M of substance P and hot spring water at a final concentration of 0.5%, and d is a blood vessel area of a skin model treated with 10. mu.M of substance P and 0.04. mu.g/mL of dexamethasone. FIG. 3 is a semi-quantitative comparison of vascular area for each group, where "NT" is a normal skin model blank control group, "NT + P substance" is a 10 μ M substance P treated skin model, "0.5% Weak + substance P" is a 10 μ M substance P co-treated skin model with a final concentration of 0.5% thermal spring water, "0.04 μ M substance + substance P" is a 10 μ M substance P co-treated skin model with 0.04 μ g/mL dexamethasone. As shown in fig. 2 and 3, after the isolated skin model was treated with 10 μ M of substance P, the blood vessel area of the isolated skin model was significantly enlarged compared to that of the normal skin model; when the skin model was treated with 0.5% daily multihot spring water or 0.04 μ g/mL dexamethasone (positive control), respectively, in combination with substance P, it was found that the blood vessel area of the ex vivo skin model after treatment with 0.5% daily multihot spring water and 0.04 μ g/mL dexamethasone was significantly reduced relative to the blood vessel area of the sensitive skin model. So a daily multihot spring water with a final concentration of 0.5% can significantly ease sensitivity by inhibiting vasodilation.
Fig. 4 is a graph comparing the mast cell degranulation rates obtained by toluidine blue staining of the groups in effect example 3, in which a is a graph of the mast cell degranulation rate of a normal skin model, b is a graph of the mast cell degranulation rate of a sensitive skin model obtained after treatment with substance P of 10 μ M, c is a graph of the mast cell degranulation rate of a skin model treated with substance P of 10 μ M and hot spring water of 0.5% final concentration, and d is a graph of the mast cell degranulation rate of a skin model treated with substance P of 10 μ M and dexamethasone of 0.04 μ g/mL. FIG. 5 is a graph of immunofluorescence semi-quantitative analysis of mast cell degranulation for each group, wherein "NT" is a normal skin model blank control group, "NT + P substance" is a 10 μ M substance P treated skin model, "0.5% Wen + substance P" is a 10 μ M substance P and final 0.5% hot spring water co-treated skin model, "0.04 μ M substance + substance P" is 10 μ M substance P and 0.04 μ g/mL dexamethasone co-treated skin model. As shown in fig. 4 and 5, after the ex vivo skin model was treated with 10 μ M of substance P by toluidine blue staining, the mast cell degranulation rate of the ex vivo skin model was significantly increased compared to that of normal skin; when ex vivo skin models were treated with diurnal hot spring water at a final concentration of 0.5% and 0.04 μ g/mL dexamethasone (positive control), respectively, in combination with substance P, it was found that the mast cell degranulation rate was significantly reduced in the ex vivo skin model relative to the sensitive skin model. So daily hot spring water with a final concentration of 0.5% can significantly ease sensitivity by reducing mast cell degranulation rates.
Claims (10)
1. The application of hot spring water in cosmetics is characterized in that the hot spring water is used as an anti-allergy active ingredient in the cosmetics; the hot spring water contains the following components per liter: na (Na)+75-114mg、Ca2+16-24mg、Mg2+0.33-0.5mg and Sr+0.36-0.55mg。
2. The use according to claim 1, wherein the hot spring water has a pH value of 6.8-7.5;
and/or, Na is added into each liter of the hot spring water+The content of (A) is 94.4 mg;
and/or, the Ca is contained in each liter of the hot spring water2+The content of (A) is 19.9 mg;
and/or, said Mg is present per liter of said spa water2+The content of (A) is 0.42 mg;
and/or, the Sr is added in each liter of the hot spring water+The content of (B) is 0.46 mg.
3. The use according to claim 2, wherein the hot spring water has a pH of 6.95 to 7.02.
4. The use according to claim 1, characterized in that said thermal spring water also contains, per litre: k+5.9-8.9mg、Li+0.4-0.63mg、Mn2+0.0168-0.0252mg、F-1.2-1.8mg、SO4 2-30-46mg and H2SiO320-32mg。
5. The use according to claim 4, wherein said thermal spring water further comprises per liter ofDividing into: k+7.4mg、Li+0.52mg、Mn2+0.021mg、F-1.5mg、SO4 2-37.9mg and H2SiO326.2mg。
6. The use according to claim 1, characterized in that the intake of hot spring water is a sunrise hot spring.
7. The use according to claim 1, wherein said spa water is sterilized by filtration through a filter membrane having a pore size of 0.22 μm.
8. The use according to claim 1, wherein the anti-sensitive active ingredient is an active ingredient that inhibits vasodilation of the skin or reduces the degranulation rate of mast cells.
9. The use according to claim 1, wherein said thermal spring water is diluted with water other than thermal spring water and then applied to the cosmetic product, the concentration of the diluted thermal spring water being 0.1% to 5%, said percentage being the volume of the thermal spring water as a percentage of the total volume of the thermal spring water and the water other than the thermal spring water.
10. The use according to claim 9, wherein the concentration of said diluted thermal spring water is between 0.5% and 1%;
and/or the water except the hot spring water is one or more of deionized water, distilled water and ultrapure water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810971992.0A CN110856695A (en) | 2018-08-24 | 2018-08-24 | Application of hot spring water in cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810971992.0A CN110856695A (en) | 2018-08-24 | 2018-08-24 | Application of hot spring water in cosmetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110856695A true CN110856695A (en) | 2020-03-03 |
Family
ID=69635440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810971992.0A Pending CN110856695A (en) | 2018-08-24 | 2018-08-24 | Application of hot spring water in cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110856695A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114295535A (en) * | 2021-12-31 | 2022-04-08 | 常州市艾斯康生物医药有限公司 | Method for rapidly detecting soothing effect of cosmetics through mast cell degranulation state |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0716280A (en) * | 1993-06-30 | 1995-01-20 | Kozaburo Shiba | Hot spring water composition for treating atopic dermatitis |
| US6106846A (en) * | 1995-09-19 | 2000-08-22 | Societe L'oreal S.A. | Use of at least one thermal spring water from Vichy as a substance P antagonist |
| CN101467950A (en) * | 2007-12-29 | 2009-07-01 | 华北制药集团新药研究开发有限责任公司 | Functional composition containing natural hot spring water for skin |
| CN106109294A (en) * | 2016-06-29 | 2016-11-16 | 广州市巧美化妆品有限公司 | A kind of moisturizing essence and preparation method thereof |
| CN106580756A (en) * | 2016-12-21 | 2017-04-26 | 湖南御家化妆品制造有限公司 | Mineral hot spring water and preparation method and application thereof |
| CN107998020A (en) * | 2017-12-18 | 2018-05-08 | 福建省海乐威生物工程有限公司 | It is a kind of that there is the face cream of antiallergy |
-
2018
- 2018-08-24 CN CN201810971992.0A patent/CN110856695A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0716280A (en) * | 1993-06-30 | 1995-01-20 | Kozaburo Shiba | Hot spring water composition for treating atopic dermatitis |
| US6106846A (en) * | 1995-09-19 | 2000-08-22 | Societe L'oreal S.A. | Use of at least one thermal spring water from Vichy as a substance P antagonist |
| CN101467950A (en) * | 2007-12-29 | 2009-07-01 | 华北制药集团新药研究开发有限责任公司 | Functional composition containing natural hot spring water for skin |
| CN106109294A (en) * | 2016-06-29 | 2016-11-16 | 广州市巧美化妆品有限公司 | A kind of moisturizing essence and preparation method thereof |
| CN106580756A (en) * | 2016-12-21 | 2017-04-26 | 湖南御家化妆品制造有限公司 | Mineral hot spring water and preparation method and application thereof |
| CN107998020A (en) * | 2017-12-18 | 2018-05-08 | 福建省海乐威生物工程有限公司 | It is a kind of that there is the face cream of antiallergy |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114295535A (en) * | 2021-12-31 | 2022-04-08 | 常州市艾斯康生物医药有限公司 | Method for rapidly detecting soothing effect of cosmetics through mast cell degranulation state |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barlow | Phytoplankton ecology in the southern Benguela current. I. Biochemical composition | |
| Freire et al. | Action of silver nanoparticles towards biological systems: cytotoxicity evaluation using hen's egg test and inhibition of Streptococcus mutans biofilm formation | |
| Lejart et al. | Respiration and calcification of Crassostrea gigas: contribution of an intertidal invasive species to coastal ecosystem CO2 fluxes | |
| Kim et al. | Macromolecular compositions of phytoplankton in the Amundsen Sea, Antarctica | |
| Morelle et al. | Dynamics of phytoplankton productivity and exopolysaccharides (EPS and TEP) pools in the Seine Estuary (France, Normandy) over tidal cycles and over two contrasting seasons | |
| Alvarez et al. | Decrease in cytotoxicity of copper-based intrauterine devices (IUD) pretreated with 6-mercaptopurine and pterin as biocompatible corrosion inhibitors | |
| CN110856695A (en) | Application of hot spring water in cosmetics | |
| Ishikawa et al. | A new method for estimating time since death by analysis of substances deposited on the surface of dental enamel in a body immersed in seawater | |
| CN107007514A (en) | A kind of draft flower water-setting dew and preparation method thereof | |
| Kumari et al. | Study of physico-chemical characteristics of water and soil in relations to fish production in Motia Lake Reservoir | |
| Bernstam et al. | Effects of arsenic on human keratinocytes: morphological, physiological, and precursor incorporation studies | |
| Valsa et al. | Time bound changes (in 24 h) in human sperm motility and level of calcium and magnesium in seminal plasma | |
| Morelle et al. | Dynamics of exopolymeric carbon pools in relation with phytoplankton succession along the salinity gradient of a temperate estuary (France) | |
| CN107523601A (en) | The preparation method and applications of scallop edge whitening peptide | |
| Farhan et al. | Synthesis of Silver Nanoparticles from Malva parviflora extract and effect on Ecto-5'-Nucleotidase (5'-NT), ADA and AMPDA enzymes in sera of patients with arthrosclerosis | |
| Hirose et al. | Oxygen nano-bubble water reduces calcium oxalate deposits and tubular cell injury in ethylene glycol-treated rat kidney | |
| Kopylov et al. | Virioplankton of the Kara Sea and the Yenisei River estuary in early spring | |
| KR20180126912A (en) | A composition for water tissue containing lava seawater | |
| EP2508886A3 (en) | Means and methods for classifying samples of multiple sclerosis patients | |
| Lamy et al. | Coastal bacterial viability and production in the eastern English Channel: A case study during a Phaeocystis globosa bloom | |
| CN110856703A (en) | Application of hot spring water in cosmetics | |
| Acuña | Summer vertical distribution of appendicularians in the central Cantabrian Sea (Bay of Biscay) | |
| US20170007640A1 (en) | Method and system for extracting and using moomiyo compositions | |
| Racy et al. | Assessment of the applicability of morphological and size diversity indices to bacterial populations of reservoirs in different trophic states | |
| Berdalet et al. | Hydrography and biochemical indicators of microplankton biomass in the Bransfield Strait (Antarctica) during January 1994 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200303 |
|
| RJ01 | Rejection of invention patent application after publication |